Safety and effectiveness of dabigatran in routine clinical practice: the RE-COVERY DVT/PE study
Abstract RE-COVERY DVT/PE is a two-phase, international, observational study of
anticoagulant therapy in patients with deep vein thrombosis and/or pulmonary embolism …
anticoagulant therapy in patients with deep vein thrombosis and/or pulmonary embolism …
Net clinical benefit of dabigatran vs. warfarin in venous thromboembolism: analyses from RE-COVER®, RE-COVER™ II, and RE-MEDY™
M Feuring, S Schulman, H Eriksson, AJ Kakkar… - Journal of Thrombosis …, 2017 - Springer
The direct oral anticoagulants, eg, dabigatran etexilate (DE), are effective and well tolerated
treatments for venous thromboembolism (VTE). Net clinical benefit (NCB) is a useful concept …
treatments for venous thromboembolism (VTE). Net clinical benefit (NCB) is a useful concept …
Dabigatran: Will it change clinical practice?
SA Wartak, JR Bartholomew - Cleveland Clinic Journal of Medicine, 2011 - europepmc.org
Dabigatran: will it change clinical practice? - Abstract - Europe PMC Sign in | Create an account
https://orcid.org Europe PMC Menu About Tools Developers Help Contact us Helpdesk …
https://orcid.org Europe PMC Menu About Tools Developers Help Contact us Helpdesk …
Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: A pooled analysis of RE-COVER™ and RE-COVER™ II
S Schulman, H Eriksson, SZ Goldhaber, A Kakkar… - Circulation, 2014 - Am Heart Assoc
Objectives: In the RE-COVER™ and RE-COVER™ II trials, dabigatran etexilate (DE)
compared with warfarin in patients with acute venous thromboembolism (VTE) resulted in …
compared with warfarin in patients with acute venous thromboembolism (VTE) resulted in …
Risk of Major Bleeding with Dabigatran Versus Active Controls: a Systematic Review and Meta-analysis of Randomised Clinical Trials
S Antoniazzi, D Berdai, V Conti, P Robinson… - Drug …, 2013 - congresso.sifweb.org
The direct thrombin inhibitor dabigatran is approved for atrial fibrillation (AF) and for
prophylaxis of venous thromboembolism (VTE) as a therapeutic alternative to warfarin and …
prophylaxis of venous thromboembolism (VTE) as a therapeutic alternative to warfarin and …
[HTML][HTML] Influence of age and renal function on efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis …
S Schulman, H Eriksson, A Kakkar, C Kearon… - Blood, 2014 - Elsevier
Abstract Background: In the RE-COVER™ and RE-COVER™ II trials, dabigatran etexilate
(DE) was as effective as warfarin (W) for prevention of recurrent venous thromboembolism …
(DE) was as effective as warfarin (W) for prevention of recurrent venous thromboembolism …
Retrospective cohort study of the efficacy and safety of dabigatran: real-life dabigatran use including very low-dose 75 mg twice daily administration
Y Akagi, T Chiba, S Uekusa, H Kato… - … Health Care and …, 2019 - Springer
Background Dabigatran is a direct thrombin inhibitor and an anticoagulant that is prescribed
to prevent ischemic stroke and systemic embolism in non-valvular atrial fibrillation …
to prevent ischemic stroke and systemic embolism in non-valvular atrial fibrillation …
Influence of Polypharmacy on the Efficacy And Safety Of Dabigatran Versus Warfarin for the Treatment of Acute Venous Thromboembolism: A Pooled Analysis of RE-COVER® …
SZ Goldhaber, H Eriksson, A Kakkar, SM Schellong… - Circulation, 2015 - Am Heart Assoc
Background: Polypharmacy in patients treated for acute venous thromboembolism (VTE)
has been associated with increased bleeding risk during warfarin (W) treatment …
has been associated with increased bleeding risk during warfarin (W) treatment …
RE-COVERY DVT/PE: Rationale and design of a prospective observational study of acute venous thromboembolism with a focus on dabigatran etexilate
The therapeutic management of venous thromboembolism (VTE) is rapidly evolving.
Following the positive results of pivotal large-scale randomised trials, the non-vitamin K …
Following the positive results of pivotal large-scale randomised trials, the non-vitamin K …
Safety and effectiveness of dabigatran relative to warfarin in routine clinical practice-new Interim results of long-term study Program
JD Seeger, DB Bartels, K Huybrechts… - Circulation, 2015 - Am Heart Assoc
Background: Dabigatran etexilate is a newer oral anticoagulant developed as an alternative
to warfarin for stroke prevention in patients with non-valvular atrial fibrillation (NVAF) …
to warfarin for stroke prevention in patients with non-valvular atrial fibrillation (NVAF) …